Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of $0.43 per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52).
Oramed Pharmaceuticals Trading Down 0.7%
Shares of NASDAQ:ORMP opened at $3.97 on Wednesday. Oramed Pharmaceuticals has a 1 year low of $2.23 and a 1 year high of $5.47. The business has a fifty day simple moving average of $4.42 and a 200 day simple moving average of $4.04. The firm has a market cap of $165.15 million, a price-to-earnings ratio of 0.96 and a beta of 1.31.
Analysts Set New Price Targets
Several research analysts have weighed in on ORMP shares. Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Wall Street Zen lowered Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating. Based on data from MarketBeat, Oramed Pharmaceuticals has a consensus rating of “Buy”.
Read Our Latest Research Report on Oramed Pharmaceuticals
Insider Buying and Selling
In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $90,200.00. Following the transaction, the chief financial officer directly owned 861,076 shares of the company’s stock, valued at $3,883,452.76. The trade was a 2.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the transaction, the chief operating officer directly owned 1,328,130 shares in the company, valued at approximately $5,989,866.30. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.77% of the company’s stock.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract. Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.
Featured Stories
- Five stocks we like better than Oramed Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
